Primary Peritoneal Cancer Therapeutics Market Size Projected to Rise Lucratively during 2026

Peritoneal cancer is a rate type of malignant tumour of the peritoneum, a layer of tissue that lines the abdomen. Peritoneal cancer develops from metastases of other tumours, mostly from gastric, intestinal, and ovarian cancers. According to Robert Koch Institute's Centre for Cancer Registry, there were around 15,600 people diagnosed with stomach cancer, 7,300 women with ovarian cancer, and 62,400 individuals with colorectal cancer in 2013. Out of the total diagnosed population, 15-20% cases have led to peritoneal metastases. Patients suffering from gastric cancer have a higher chance (30%) of developing peritoneal cancer at some point in their disease. The survival rate of peritoneal cancer, if left untreated, is around 3-6 months. Peritoneal cancer is sometimes left untreated, as it cannot be detected by radiological imaging. This is the main reason for lower reported incidences of peritoneal cancer, and hence, it is considered as a very rare form of cancer.

Primary Peritoneal Cancer Therapeutics Market: Drivers and Restraints

The growing number of reported incidences of peritoneal cancer due to increased awareness is anticipated to boost the growth of the primary peritoneal cancer therapeutics market. The increasing number of patients suffering from metastatic gastric, intestinal, and ovarian cancers is expected to increase the incidences of peritoneal cancer, which would lead to an increase in the demand for primary peritoneal cancer therapeutics. The growing demand for a multidisciplinary treatment regime in closed care and increased spending on palliative care for patient in the end stage of disease are likely boost the growth of the primary peritoneal cancer therapeutics market. However, limitation in terms of targeted therapy and lack of effective diagnostic technologies are expected to hamper the growth of the primary peritoneal cancer therapeutics market.

Request for Report Sample : https://www.persistencemarketresearch.com/samples/24115

Primary Peritoneal Cancer Therapeutics Market: Segmentation

Tentatively, the global primary peritoneal cancer therapeutics market has been segmented on the basis of treatment type, end user, and geography.

Based on treatment type, the global primary peritoneal cancer therapeutics market is segmented as:

Chemotherapy
Targeted Therapy
Hormonal Therapy
Radiation Therapy
Surgical Intervention
Based on end user, the global primary peritoneal cancer therapeutics market is segmented as:

Hospitals
Cancer Research Centers
Ambulatory Surgical Centers

Request for Report TOC : https://www.persistencemarketresearch.com/toc/24115

About Us

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Contact Us

Persistence Market Research
305 Broadway
7th Floor, New York City,
NY 10007, United States,
USA,Canada Toll Free: 800-961-0353
Email: sales@persistencemarketresearch.com
Web: http://www.persistencemarketresearch.com

This release was published on openPR.